EichorEICHOR
Study identifier: NCT07158437 Synced from ClinicalTrials.gov · August 11, 2026
● Study status: Active Not Recruiting

Phase 1 Study of SL-325 in Healthy Volunteers

Condition: Healthy Volunteers  ·  Sponsor: Shattuck Labs, Inc.

PhasePhase 1
Planned participants72
Who can joinAll sexes, 18 Years to 55 Years
Healthy volunteersYesCheck eligibility criteria ↓
WhereLincoln, Nebraska, United States
For sponsors, CROs & site teams
Professional view of this study — listed sites, countries and recruiting context from the public registry. Everything below is written for patients and caregivers.See where this study is running →

About this study

This first-in-human study is a randomized, double-blind, placebo-controlled, single-ascending dose and multiple-ascending dose study of SL-325 in healthy volunteers.

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: 1. Provide signed informed consent 2. 18-55 years of age, inclusive, at the time of signing the informed consent form 3. Body mass index of 18-32 kg/m2, inclusive, and a total body weight \> 50 kg 4. Laboratory values within normal limits or any abnormalities deemed not clinically significant by the Investigator 5. Participant agrees to practice birth control measures Exclusion Criteria: 1. History or presence of a clinically significant infectious disease or hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, neurologic, or psychiatric abnormality 2. Any clinically significant abnormality on vital signs, electrocardiogram (ECG), or laboratory parameters 3. History of regular alcohol consumption within 6 months of Screening 4. Positive test for use of drugs or alcohol at Screening 5. History of use of tobacco- or nicotine-containing products within 3 months of Screening 6. History of infusion-related reaction or allergic reaction upon receipt of an IV infusion 7. Positive hepatitis B virus, hepatitis C virus, or human immunodeficiency virus (HIV) test at Screening 8. Blood donation within 90 days prior to Day -1 or plasma donation within 1 week prior to Day 1 9. Receipt of specific medications within a specified time period 10. Women who are currently breastfeeding or have a positive pregnancy test

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (1)

CelerionLincoln, Nebraska, United States

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

Lincoln

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →